Side-by-side · Research reference

GlutathionevsTeriparatide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticHUMAN-REVIEWED6/39 cited

BFDA-ApprovedHUMAN-REVIEWED10/62 cited

Glutathione

Endogenous Tripeptide · Antioxidant

γ-Glu-Cys-GlyStructure

UbiquitousTissue distribution

GCL + GSBiosynthesisWang 2026 Aiana 2026

IV · Oral · Inhaled

Teriparatide

PTH (1-34) Fragment · FDA-Approved

20 mcgDaily dose

12-18 moAnabolic windowFerrari 2026

SQRoute

SQ · Thigh/Abdomen · Once Daily

01Mechanism of Action

Parameter

Glutathione

Teriparatide

Primary target

Intracellular redox systems, glutathione peroxidase, glutathione transferase

Parathyroid hormone 1 receptor (PTH1R) on osteoblastsXue 2026

Pathway

Synthesized via glutamate-cysteine ligase (GCL) → γ-glutamylcysteine → glutathione synthetase (GS) → GSH

PTH1R activation → cAMP/PKA signaling → osteoblast differentiation and activity

Downstream effect

Reduction of reactive oxygen species, conjugation of electrophiles, maintenance of cellular thiol-disulfide balance, GPX4 activation for lipid peroxide reduction

Stimulates osteoblast formation and bone matrix deposition; increases bone mineral density at trabecular and cortical sites

Feedback intact?

—

Yes — intermittent dosing preserves anabolic effect; continuous exposure causes catabolic bone resorption

Origin

Endogenous tripeptide; predominantly synthesized in liver, exported to extracellular space and tissuesTerrell 2025 Hecht 2026

Recombinant 34-amino-acid N-terminal fragment of 84-amino-acid human PTH

Antibody development

—

02Dosage Protocols

Parameter

Glutathione

Teriparatide

Endogenous synthesis

Hepatic synthesis ~10 g/day (basal rate)

Tissue-specific; demand-driven upregulation via Nrf2 signaling.

—

Exogenous oral

250–1000 mg/day

Bioavailability limited; gastric hydrolysis reduces systemic uptake.

—

IV supplementation

600–1200 mg (research protocols)

Used in clinical oxidative stress and hepatic detoxification studies.

—

Precursor strategy

N-acetylcysteine (NAC) 600–1200 mg/day

Provides cysteine for endogenous GSH synthesis; bypasses GI degradation.

—

Evidence basis

Animal mechanistic + human mechanistic

RCT / FDA-approved

Standard dose (osteoporosis)

—

20 mcg / day

FDA-approved regimen for severe osteoporosis.

Frequency

—

Once daily

Intermittent administration preserves anabolic effect.

Maximum duration

—

24 months lifetime

Anabolic effect wanes after 12-18 months; FDA recommends max 2-year cumulative exposure.

Hypoparathyroidism dose

—

20 mcg / day

Used off-label for chronic hypoparathyroidism.

Pelvic fragility fractures

—

20 mcg / day × 8-12 weeks

Accelerates fracture healing; reduces time to union.Crooks 2026

Route

—

Subcutaneous (thigh or abdomen)

Timing

—

Morning or evening (flexible)

Storage

—

Refrigerate 2-8 °C; pen device stable at room temp for 28 days after first use

Pharmacogenetics

—

ALDH2 polymorphisms may influence BMD responseObara 2026

ALDH2*2 variant carriers show altered PTH receptor expression.Obara 2026

03Metabolic / Fat Loss Evidence

Parameter

Glutathione

Teriparatide

Fat loss application

—

None — teriparatide is a bone anabolic agent without direct lipolytic activity

04Side Effects & Safety

Parameter

Glutathione

Teriparatide

Oral supplementation

GI discomfort, bloating (mild, dose-dependent)

—

IV administration

Rare hypersensitivity, infusion site reaction

—

Inhalation

Bronchospasm risk in asthma (rare)

—

Tumor metabolism

Extracellular GSH catabolism supplies cysteine to tumors; theoretical concern in active malignancyHecht 2026

—

Hypercalcemia

—

Transient serum calcium elevation 4-6 hours post-injection

Monitor serum calcium; usually asymptomatic.

Orthostatic hypotension

—

Dizziness, lightheadedness within hours of injection

Nausea

—

Common, usually mild and transient

Leg cramps / Arthralgia

—

Musculoskeletal pain reported in clinical trials

Hypercalciuria

—

Increased urinary calcium excretion; monitor for nephrolithiasis risk

Osteosarcoma (black box warning)

—

Rat studies showed dose-dependent osteosarcoma; not observed in humans to date; contraindicated in Paget's disease, skeletal malignancy, prior radiation

Injection site reaction

—

Erythema, bruising, pain (uncommon)

Absolute Contraindications

Glutathione

—

Teriparatide

·Paget's disease of bone (increased baseline osteosarcoma risk)
·Unexplained elevated alkaline phosphatase
·Prior skeletal radiation therapy
·Skeletal malignancies or bone metastases
·Hypercalcemic disorders (primary hyperparathyroidism)
·Pregnancy / lactation

Relative Contraindications

Glutathione

·Active malignancy (theoretical cysteine supply risk)Hecht 2026
·Severe asthma (inhaled formulations)

Teriparatide

·Active or recent nephrolithiasis
·Severe renal impairment (CKD G4-G5)
·Hypercalciuria without adequate monitoring

05Administration Protocol

Parameter

Glutathione

Teriparatide

1. Oral administration

Capsule or liquid form, 250–1000 mg once daily. Take on empty stomach for improved absorption, though GI hydrolysis limits bioavailability. NAC precursor strategy often preferred.

Teriparatide is supplied in pre-filled pen injectors (Forteo pen). Store refrigerated at 2-8 °C until first use. After first injection, pen may be kept at room temperature for up to 28 days. Do not freeze.

2. Intravenous

Clinical protocols: 600–1200 mg slow infusion over 30–60 minutes. Used for acute oxidative stress, hepatic detoxification support. Administered in medical settings.

Subcutaneous injection into thigh or lower abdomen. Rotate sites daily to avoid lipodystrophy. Avoid areas with scars, bruises, or active skin conditions.

3. Inhaled formulations

Nebulized GSH (research protocols). Monitor for bronchospasm in reactive airway patients. Used experimentally for pulmonary oxidative stress.

Once daily, at approximately the same time each day. Morning or evening administration is acceptable. Take while sitting or lying down to minimize orthostatic hypotension risk.

4. Precursor supplementation

N-acetylcysteine (NAC) 600–1200 mg/day PO. Provides cysteine substrate for endogenous GSH synthesis. Bypasses gastric degradation, preferred for chronic supplementation.

Clean injection site with alcohol swab. Pinch skin, insert needle at 90° angle, and inject full dose (20 mcg). Hold for 5 seconds before withdrawing needle. Do not rub injection site.

5. Monitoring

—

Baseline and periodic monitoring of serum calcium, urinary calcium, serum PTH (if hypoparathyroidism), and bone mineral density (DXA scan). Monitor for hypercalcemia 4-6 hours post-dose if symptomatic.

6. Calcium and vitamin D supplementation

—

Ensure adequate calcium (1000-1200 mg/day) and vitamin D (800-1000 IU/day) intake unless contraindicated by hypercalcemia or hypercalciuria.